New Korean paper below [1].
The study was on "203 patients with undetectable {PSA} who had undergone radical prostatectomy".
Over a third had circulating tumor cells [CTCs] ("at a median of 4.5 months after surgery.")
"CTC detection was independently associated with an increased risk of biochemical recurrence (HR=5.42 ...)"
My prostatectomy was an immediate failure. I wonder what the incidence of CTCs is when PSA is not zero after surgery?
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/318...
J Urol. 2019 Dec 17:101097JU0000000000000704. doi: 10.1097/JU.0000000000000704. [Epub ahead of print]
Association Between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
Pak S1, Suh YS1,2, Lee DE3, Kim SH1, Joung JY1, Park WS4, Lee SJ5, Lee KH1.
Author information
1
Department of Urology, Center for Urologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
2
Seoul Urology Clinic, Seoul Urology Group, Seoul, Korea.
3
Biostatistics Collaboration Team, Research Core Center, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
4
Department of Pathology, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
5
Division of Cancer Immunology, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Abstract
PURPOSE:
The clinical implications of postoperative detection of circulating tumor cells (CTCs) in prostate cancer are largely unknown. This study aimed to investigate the association between postoperative CTC detection after radical prostatectomy and disease recurrence in prospectively enrolled patients with prostate cancer.
METHODS:
A total of 203 patients with undetectable prostate-specific antigen (PSA) who had undergone radical prostatectomy for prostate cancer were prospectively enrolled. CTC sampling was performed at a median of 4.5 months after surgery. The primary endpoint was biochemical recurrence-free survival. Detection of CTCs in the blood of patients was performed using a novel approach with a replication competent adenovirus controlled by PSA/prostate-specific membrane antigen transcription regulatory elements (Ad5/35E1aPSESE4).
RESULTS:
CTCs were detected in 73 (36.0%) patients with undetectable PSA concentrations after surgery. The 3-year biochemical recurrence-free survival rate from the time of surgery was significantly higher in CTC-negative patients than in CTC-positive patients (81.6% vs 48.9%, log rank p<0.001). Multivariable analysis showed that postoperative CTC detection was independently associated with an increased risk of biochemical recurrence (HR=5.42; 95% CI, 3.24-9.06; p<0.001). C-index was increased in the combination of multivariable model and postoperative CTC detection compared with multivariable model alone.
CONCLUSIONS:
CTCs in the blood were frequently detected in patients with undetectable PSA levels after radical prostatectomy for localized prostate cancer. Furthermore, CTC detection was associated with an increased risk of biochemical recurrence, suggesting that CTC detection precedes PSA rise after surgery in case of prostate cancer recurrence. Large-scale validation is needed in the future.
KEYWORDS:
biomarkers; circulating tumor cells; prostate cancer; recurrence
PMID: 31845840 DOI: 10.1097/JU.0000000000000704